{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "LQDA",
  "name": "Liquidia Corporation",
  "url": "https://frontierpicks.com/dossiers/LQDA/",
  "json_url": "https://frontierpicks.com/dossiers/LQDA.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "The prior break level triggered: LQDA closed the week at $68.62 on 2026-08-21, through the $70 July shelf and the 08-13 low close of $72.10, despite six post-print targets at $90–$111. Q2 sales grew +31% QoQ, but the re-rating leg is broken and there is no dated catalyst before a ~2026-11-10 Q3 print. The undated '327 bench ruling is the only near-term binary.",
  "invalidation_trigger": "A weekly close below $65 puts the shares under the entire May 2026 post-Q1 target cluster ($59–$70) and confirms the market is repricing the >$1B 2027 guide. Secondary: a '327 docket entry granting permanent PH-ILD injunctive relief, or Q3 YUTREPIA net sales at or below Q2's $170.4M.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "precision-biotech-therapeutics",
    "binary-catalyst-biotech"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Single-product concentration: YUTREPIA was $170.4M of $171.7M total Q2'26 revenue. No second commercial product absorbs a label or legal shock.",
    "Event risk with no date: the '327 bench ruling (D. Del. 1:23-cv-00975, PH-ILD only) was still outstanding as of the 2026-08-12 call and can land in any session.",
    "Full FDA approval (2025-05-23, both PAH and PH-ILD) stands independent of '327, which reads on the PH-ILD indication only.",
    "S&P SmallCap 600 member since 2026-06-22 — a portion of daily flow is index-driven small-cap beta rather than company news.",
    "CEO share sales run under a Rule 10b5-1 plan adopted in December 2023, so individual sale dates are scheduled rather than discretionary.",
    "Management guided R&D spend to double in H2 2026 across ten planned or ongoing studies, so Q2's $74.7M net income is not a clean run-rate."
  ],
  "body_markdown": "## Current Thesis\nThe break level named in the prior note came and went. On **2026-08-21** LQDA closed the week at **$68.62**, through the **$70** July shelf and below the post-print low close of **$72.10** set on 2026-08-13. That is the second leg of a rejection that began with the **2026-08-12** Q2 print — a quarter that was, on the operating numbers, the best the company has reported: YUTREPIA net product sales **$170.4M, +31% sequential** off Q1's **$129.9M**, total revenue **$171.7M**, net income **$74.7M** ($0.84 basic / $0.74 diluted), cash **$284.2M** at 6/30/26 against $190.7M at 12/31/25. Six houses moved targets into **$90–$111** across 08-12 and 08-13 — Raymond James went to **$106 from $68** (Strong Buy, 08-13), BTIG **$111**, Needham **$110**, Wells Fargo **$108**, BofA **$92**, and LifeSci Capital cut to Market Perform at **$90**. None of it produced a bid. The three-month price change has compressed from **+30.8%** as measured on 2026-08-14 to **+12.5%** on 2026-08-21, and the shares now sit **-24.6%** from the **$91.03** 52-week high with RSI(14) at **32.2**. The commercial ramp and the equity narrative have decoupled; the undated **'327** bench ruling from Judge Andrews (D. Del. 1:23-cv-00975, PH-ILD only) remains the one event that can re-rate either direction, and it has no calendar entry.\n\n## Bull Case\n- **The growth line has not bent.** Q2'26 YUTREPIA net product sales $170.4M, +31% QoQ; management said on the 2026-08-12 call that YUTREPIA's growth alone exceeded growth of the entire inhaled prostacyclin category, with share approaching **30% of that market by net revenue**.\n- **Patient base is a counted number.** Approximately **5,900 unique patient prescriptions and more than 5,000 patients treated** from the June 2025 launch through **2026-07-31**, disclosed with Q2 results.\n- **Funded from operations.** Cash and equivalents **$284.2M** at 2026-06-30, **+$61.4M** on the quarter, with no issuance required to carry the launch.\n- **The Street's numbers went up while the price went down.** Average target of **$98.08** across a book of 1 Strong Buy, 5 Buy, 3 Hold and 2 Sell as tabulated 2026-08-22; management reiterated **>$1B net revenue in 2027** on the Q2 call.\n- **The legal tail narrowed before it widened.** Full FDA approval (**2025-05-23**, PAH and PH-ILD) is independent of '327, which reads on PH-ILD only; the **2026-06-04** SCOTUS decision in Hikma v. Amarin raised the induced-infringement bar for skinny labels.\n\n## Bear Case\n- **Every bounce has been sold within two sessions.** Shares rose 4.3% to **$77.70 on 2026-08-17**, fell **5.8% to $71.05 on 2026-08-20**, and closed **$68.62 on 2026-08-21**. A rally attempt inside a target cluster of $90–$111 that fails in three days says the marginal buyer was already positioned into the print.\n- **Insiders sold into the drawdown.** Form 4 activity reported 2026-08-22 shows Chief Medical Officer Rajeev Saggar selling **29,534 shares at an average $76.84 on 2026-08-17** and **50,000 shares at an average $74.06 on 2026-08-19**, leaving 142,265 shares. GuruFocus, summarising the trailing three months as of 2026-08-20, put insider sales at **$160.2M against $0.3M of buying**.\n- **Single molecule, undated injunction risk.** YUTREPIA was $170.4M of $171.7M in Q2 revenue. Management told the Q2 call it has no visibility into Judge Andrews' timeline and that an adverse outcome could produce royalties **or injunctive relief**.\n- **The earnings line bends in H2.** R&D spend was guided to **double in H2 2026** across ten studies underway or planned within twelve months, so the $74.7M quarterly net income is not a run-rate to extrapolate.\n- **No dated catalyst for roughly eleven weeks.** Q1 printed 2026-05-11, Q2 on 2026-08-12; the next scheduled disclosure is a Q3 report around 2026-11-10. Between now and then the only scheduled flow is index and sector beta.\n\n## Setup & Price Structure\nReference close **$68.62** (2026-08-21), **-24.6%** from the **$91.03** 52-week high, RSI(14) **32.2**. The July breakout shelf at **$70** is gone; the 2026-08-13 post-print low close of **$72.10** is gone; the 2026-08-17 recovery to $77.70 lasted two sessions. Price sits below all six post-print targets and below the **$98.08** average. Positioning observables, stated as observables: institutional ownership **64.54%** (2026-08-22 tabulation), S&P SmallCap 600 membership since **2026-06-22** so a portion of daily volume is index-driven, and two insider sales in the week ended 08-21 at $74–$77 while the stock was falling. RSI in the low 30s with no dated event inside 30 days is an oversold reading without a scheduled reason to resolve.\n\n**The narrative is dead.** Dated by the 2026-08-21 weekly close of $68.62, which broke the shelf the July advance was built on, and by the failure of six target actions on 08-12/08-13 to attract a bid. This label is about the price narrative, not the P&L: the operating story is still compounding at +31% sequential. What died is the re-rating leg — the market has stopped paying up for each incremental sales datapoint. A new leg requires a new fact, and the two candidates ('327, Q3 sales) are one undated and one eleven weeks out.\n\n## Catalyst Calendar (next 30 days)\n\n- **No scheduled company catalyst between 2026-08-23 and 2026-09-22.** The Q2 8-K landed 2026-08-12; the Q3 report is expected around **~2026-11-10 (est.)** on the pattern of 05-11 and 08-12 prints.\n- **~2026-11-10 (est.):** Q3 FY26 print — first read on whether YUTREPIA clears $170.4M and what the doubled H2 R&D does to the net income line.\n\n## Elapsed catalysts\n\n- **Undated, live in every session:** Judge Andrews' '327 bench ruling, D. Del. 1:23-cv-00975. Pending with no disclosed timeline as of the 2026-08-12 call. *(passed 14d ago)*\n\n## What Would Change Our Mind\nThe structural argument that fails first is sequential growth: Q3 YUTREPIA net sales at or below **$170.4M**, or inhaled-prostacyclin share stalling below 30% of net revenue, would mean the switch cohort is exhausted and the >$1B 2027 guide is the wrong anchor. Second, a '327 docket entry ordering permanent injunctive relief on PH-ILD rather than damages or an ongoing royalty removes part of the only revenue engine with no notice. On price, a **weekly close below $65** would put the shares under the entire May 2026 post-Q1 target cluster ($59–$70 across BTIG, Wells Fargo, HC Wainwright and Needham on 05-11/05-12) and say the market is repricing the 2027 guide rather than digesting a print. In the other direction: a weekly close back above **$77.70** (the failed 2026-08-17 high close) with the 08-19/08-20 distribution absorbed, or a damages-only '327 outcome, would put the narrative back into a live phase and make the gap to the $98.08 average target the operative question again.\n\n## Correlation Notes\n- **United Therapeutics is the direct counterweight.** YUTREPIA's share gains come out of Tyvaso DPI; UTHR guidance on Tyvaso revenue and retained share at its next print is the cleanest external read on whether the ramp converts to net revenue or to gross-to-net discounting.\n- **Index beta since 2026-06-22.** S&P SmallCap 600 inclusion means part of daily flow tracks small-cap risk appetite rather than company news — relevant when reading a -5.8% session like 2026-08-20 with no company headline attached.\n- **Sector beta.** Single-product commercial-stage biotech trades with the biotech complex on rate and risk moves; the 2026-08-17 to 2026-08-21 path (+4.3%, then -5.8%, then a lower weekly close) ran without a company-specific news item.\n- **Litigation is idiosyncratic.** The '327 ruling is uncorrelated with sector or index flow and can arrive on any docket day, which is why the drawdown carries an event overhang a comparable non-litigating name would not.",
  "first_seen": "2026-05-14",
  "last_analyzed": "2026-08-23T14:00:16+00:00",
  "last_synthesized": "2026-08-23",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}